Aaron Wei Liang Li

Mr. Aaron Wei Liang Li

National University of Singapore, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMadhuvanthi Chandrakanthan
Madhuvanthi Chandrakanthan
TNToan Quoc Nguyen
Toan Quoc Nguyen
ZHZafrul Hasan
Zafrul Hasan
SMSneha Muralidharan
Sneha Muralidharan
TVThiet Minh Vu
Thiet Minh Vu
LNLong N. Nguyen
Long N. Nguyen
We recently discovered that Mfsd2b, which is the S1P exporter found in blood cells. Here, we report that Mfsd2b is critical for the release of all S1P species in both resting and activated platelets. We show that resting platelets store S1P in the cytoplasm. After activation, this S1P pool is delivered to the plasma membrane, where Mfsd2b is predominantly localized for export. Employing knockout mice of Mfsd2b, we reveal that platelets contribute a minor amount of plasma S1P. Nevertheless, Mfsd2b deletion in whole body or platelets impairs platelet morphology and functions. In particular, Mfsd2b knockout mice show significantly reduced thrombus formation. We show that loss of Mfsd2b affects intrinsic platelet functions as part of remarkable sphingolipid accumulation. These findings indicate that accumulation of sphingolipids including S1P by deletion of Mfsd2b strongly impairs platelet functions, which suggests that the transporter may be a target for the prevention of thrombotic disorders.

25 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Cho Yeow KohCho Yeow Koh
Cho Yeow Koh
NSNorrapat Shih
Norrapat Shih
CYChristina Y. C. Yip
Christina Y. C. Yip
ALAaron Wei Liang Li
Aaron Wei Liang Li
WCWeiming Chen
Weiming Chen
MCMark Y Chan
Mark Y Chan
Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a Ki of 4.0 pM, 445-fold better than bivalirudin. Unexpectedly, despite their greater antithrombotic effect, variegin/ultravariegin demonstrated less bleeding, achieving a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models. When used in combination with aspirin and ticagrelor in a porcine model, variegin/ultravariegin reduced stent thrombosis compared with antiplatelet therapy alone but achieved a 5-to-7-fold lower bleeding time than UFH/bivalirudin. Moreover, two antibodies screened from a naïve human antibody library effectively reversed the anticoagulant activity of ultravariegin, demonstrating proof-of-principle for antidote reversal. Variegin and ultravariegin are promising translational candidates for next-generation DTIs that may reduce peri-PCI bleeding in the presence of antiplatelet therapy.

16 October 2024 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XSXia Song
Xia Song
YWYuting Wen
Yuting Wen
ALAaron Wei Liang Li
Aaron Wei Liang Li
JZJingling Zhu
Jingling Zhu
Cho Yeow KohCho Yeow Koh
Cho Yeow Koh
Jun LiJun Li
Jun Li

12 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
WCWei Seng Chng
Wei Seng Chng
ALAaron Wei Liang Li
Aaron Wei Liang Li
JLJasmine Jia Min Lim
Jasmine Jia Min Lim
ELEsther Jia En Leong
Esther Jia En Leong
FAFathiah S. Amran
Fathiah S. Amran
Cho Yeow KohCho Yeow Koh
Cho Yeow Koh
Activated factor XI (FXIa) is an important antithrombotic drug target. Clinical and pre-clinical data have demonstrated that its inhibition attenuates thrombosis with minimal risk of excessive bleeding. We isolated Fasxiator from the venom of banded krait Bungarus fasciatus and subsequently engineered FasxiatorN17R,L19E, with improved affinity (Ki = 0.9 nM) and selectivity towards FXIa. Here, we assess the in vivo efficacy and bleeding risk of rFasxiatorN17R, L19E in pre-clinical animal models. Rats injected intravenously (i.v.) with bolus rFasxiatorN17R, L19E showed the specific in vivo attenuation of the intrinsic coagulation pathway, lasting for at least 60 min. We performed the in vivo dose-ranging experiments for rFasxiatorN17R, L19E as follows: FeCl3-induced carotid artery occlusion in rats (arterial thrombosis); inferior vena cava ligation in mice (venous thrombosis); tail bleeding time in both rats and mice (bleeding risk). Head-to-head comparisons were made using therapeutic dosages of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) for arterial and venous thrombosis, respectively. In the arterial thrombosis model, 2 mg/kg i.v. rFasxiatorN17R,L19E achieved a similar antithrombotic efficacy to that of UFH, with >3-fold lower bleeding time. In the venous thrombosis model, the 10 mg/kg subcutaneous (s.c.) injection of rFasxiatorN17R,L19E achieved similar efficacy and bleeding levels to those of LMWH enoxaparin. Overall, rFasxiatorN17R,L19E represents a promising molecule for the development of FXIa-targeting anticoagulants.

20 December 2024 in Journal of Molecular and Cellular Cardiology Plus
Verified
Journal Article
Open access
DLDan Liao
Dan Liao
ALAaron Wei Liang Li
Aaron Wei Liang Li
CPCinthia Wan Ting Phua
Cinthia Wan Ting Phua
CCCheryl Xue Pei Chuah
Cheryl Xue Pei Chuah
XYXiao Xun Yang
Xiao Xun Yang
CKCho Yeow Koh
Cho Yeow Koh

1 April 2020 in Toxicon
Verified
Journal Article
Closed access
CKCho Yeow Koh
Cho Yeow Koh
ALAaron Wei Liang Li
Aaron Wei Liang Li
WCWan Chen
Wan Chen
TKTse Siang Kang
Tse Siang Kang
ELEsther Jia En Leong
Esther Jia En Leong
RKR Manjunatha Kini
R Manjunatha Kini